Healthcare Global Enterprises Intrinsic Value
HCG • Healthcare Services
Current Stock Price
₹527.70
Primary Intrinsic Value
₹158.31
Market Cap
₹7335 Cr
-70.0%
Downside
Median Value
₹158.31
Value Range
₹106 - ₹310
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%
HCG Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹158.31 | ₹126.65 - ₹189.97 | -70.0% | EPS: ₹4.64, Sector P/E: 12x |
| Book Value Method | asset | ₹105.54 | ₹94.99 - ₹116.09 | -80.0% | Book Value/Share: ₹71.22, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹158.31 | ₹142.48 - ₹174.14 | -70.0% | Revenue/Share: ₹186.47, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹215.83 | ₹194.25 - ₹237.41 | -59.1% | EBITDA: ₹500.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹309.78 | ₹247.82 - ₹371.74 | -41.3% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹158.31 | ₹142.48 - ₹174.14 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹158.31 | ₹142.48 - ₹174.14 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹263.85 | ₹237.47 - ₹290.24 | -50.0% | ROE: 8.5%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹158.31 | ₹142.48 - ₹174.14 | -70.0% | EPS: ₹4.64, BVPS: ₹71.22 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
HCG Intrinsic Value Analysis
What is the intrinsic value of HCG?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Healthcare Global Enterprises (HCG) is ₹158.31 (median value). With the current market price of ₹527.70, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹105.54 to ₹309.78, indicating ₹105.54 - ₹309.78.
Is HCG undervalued or overvalued?
Based on our multi-method analysis, Healthcare Global Enterprises (HCG) appears to be trading above calculated value by approximately 70.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.56 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 8.5% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.73x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Healthcare Global Enterprises
Additional stock information and data for HCG
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹317 Cr | ₹73 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹285 Cr | ₹172 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹252 Cr | ₹186 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹220 Cr | ₹220 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹121 Cr | ₹36 Cr | Positive Free Cash Flow | 7/10 |